^
Association details:
| Biomarker: | FGFR1 expression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | derazantinib (ARQ 087) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5501 - Derazantinib, an FGFR1-3 inhibitor, inhibits CSF1R in macrophages and tumor cell lines, and synergizes with a PDL1-antibody in an FGFR-driven murine syngeneic model
Published date:
03/09/2022
Excerpt:
In the FGFR-driven syngeneic tumor-model, 4T1, DZB was highly efficacious causing tumor-stasis. The PDL1-Ab was without efficacy in this model, but in combination with DZB, increased efficacy against the primary tumor, and more strongly against the liver and lung metastases....In combination with a murine PDL1-Ab, DZB showed a positive interaction in the orthotopic syngeneic breast tumor model, 4T1, against both the primary tumor and metastases.
Secondary therapy:
Undisclosed anti-PD-L1 antibody
